Technology insight: Targeting of biological molecules for evaluation of high-risk atherosclerotic plaques with magnetic resonance imaging

Nature Clinical Practice Cardiovascular Medicine

Volumn 1, Issue 1, 2004, Pages 48-55

  Lipinski, Michael J ^a   Fuster, Valentin ^a   Fisher, Edward A ^b   Fayad, Zahi A ^c  

^a Zena and Michael A Wiener Cardiovascular Institute   (United States)

^b Marc and Ruti Bell Vascular Biology and Disease Program   (United States)

^c Imaging Science Laboratories   (United States)

Author keywords

Atherogenesis; Biological markers; Contrast agents; High risk atherosclerotic plaque; Magnetic resonance imaging

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8A; CD36 ANTIGEN; CONTRAST MEDIUM; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRIN; GELATINASE A; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; LIPOPROTEIN; PADGEM PROTEIN; SCAVENGER RECEPTOR; SCLEROPROTEIN; THROMBOPLASTIN; VASCULAR CELL ADHESION MOLECULE 1; VITRONECTIN RECEPTOR;

ATHEROSCLEROTIC PLAQUE; BIOTECHNOLOGY; DISEASE COURSE; EXTRACELLULAR MATRIX; FOAM CELL; HIGH RISK PATIENT; HUMAN; MACROPHAGE; MOLECULAR BIOLOGY; MORBIDITY; MORTALITY; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; CONTRAST MEDIA; EMBOLISM, CHOLESTEROL; ENDOTHELIUM, VASCULAR; HUMANS; LIPOPROTEINS; MAGNETIC RESONANCE IMAGING;

EID: 20444493524     PISSN: 17434297     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpcardio0013     Document Type: Review

References (50)

1. American Heart Association (2004) Heart Disease and Stroke Statistics - 2004 Update. [http://www.americanheart.org/downloadable/heart/ 1079736729696HDSStats2004UpdateREV3-1904.pdf] (accessed 11 Aug 04)
2. Malek AM et al. (1999) Hemodynamic shear stress and its role in atherosclerosis. JAMA 282: 2035-2042
3. Vanhoutte PM (2003) Endothelial dysfunction and atherosclerosis. Eur Heart J 18: E19-29
4. Cushing S et al. (1990) Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. PNAS 87: 5134-5138
5. Goldstein JL et al. (1979) Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 76: 333-337
6. Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809.
7. Richardson PD et al. (1989) Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 2: 941-944
8. Falk E (1983) Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis: characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 50: 127-134
9. Jones CB et al. (2003) Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 59: 812-823
10. Nunn AD et al. (1997) Can receptors be imaged with MRI agents? Q J Nucl Med 41: 155-162
11. Aime S et al. (2002) Insights into the use of paramagnetic Gd(III) complexes in MR-molecular imaging investigations. J Magn Reson Imaging 16: 394-406
12. Suzuki H et al. (1997) A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 386: 292-296
13. Gough PJ et al. (1999) Analysis of macrophage scavenger receptor (SR-A) expression in human aortic atherosclerotic lesions. Arterioscler Thromb Vasc Biol 19: 461-471
14. Nakata A et al. (1999) CD36, a novel receptor for oxidized low-density lipoproteins, is highly expressed on lipid-laden macrophages in human atherosclerotic aorta. Arterioscler Thromb Vasc Biol 19: 1333-1339
15. Weissleder R et al. (1990) Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 175: 489-493
16. Saini S et al. (1987) Ferrite particles: a superparamagnetic MR contrast agent for the reticuloendothelial system. Radiology 162: 211-216
17. Weissleder R et al. (1990) Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 175: 494-498
18. Litovsky S et al. (2003) Superparamagnetic iron oxide-based method for quantifying recruitment of monocytes to mouse atherosclerotic lesions in vivo: enhancement by tissue necrosis factor-α, interleukin-1β, and interferon-γ. Circulation 107: 1545-1549
19. Kanno S et al. (2001) Macrophage accumulation associated with rat cardiac allograft rejection detected by magnetic resonance imaging with ultrasmall superparamagnetic iron oxide particles. Circulation 104: 934-938
20. Ruehm SG et al. (2001) Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation 103: 415-422
21. Kooi ME et al. (2003) Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 107: 2453-2458
22. Tsimikas S (2002) Noninvasive imaging of oxidized low-density lipoprotein in atherosclerotic plaques with tagged oxidation-specific antibodies. Am J Cardiol 90: 22L-27L
23. Ehara S et al. (2001) Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103: 1955-1960
24. Tsimikas S et al. (1999) Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo. J Nucl Cardiol 6: 41-53
25. Tsimikas S et al. (2000) In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. Arterioscler Thromb Vasc Biol 20: 689-697
26. Brooks PC et al. (1994) Requirement of vascular Radiology 221: 237-243
27. O'Brien ER et al. (1994) Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol 145: 883-894
28. Winter PM et al. (2003) Molecular imaging of angiogenesis in early-stage atherosclerosis with αvβ3-integrin-targeted nanoparticles. Circulation 108: 2270-2274
29. Winter PM et al. (2003) Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel αvβ3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res 63: 5838-5843
30. Anderson SA et al. (2000) Magnetic resonance contrast enhancement of neovasculature with αvβ3-targeted nanoparticles. Magn Reson Med 44: 433-439
31. Volker W et al. (1989) Cytochemical changes in a human arterial proteoglycan related to atherosclerosis. Atherosclerosis 77: 117-130
32. Kolodgie FD et al. (2002) Differential accumulation of proteoglycans and hyaluronan in culprit lesions: insights into plaque erosion. Arterioscler Thromb Vasc Biol 22: 1642-1648
33. Wallner K et al. (1999) Tenascin-C is expressed in macrophage-rich human coronary atherosclerotic plaque. Circulation 99: 1284-1289
34. Aguinaldo JGS et al. (2002) Atheroslcerotic plaque imaging using a novel contrast agent gadofluorine M [Abstract]. Mol Imaging 2: s282
35. Barkhausen J et al. (2003) Detection of atherosclerotic plaque with gadofluorine-enhanced magnetic resonance imaging. Circulation 108: 605-609
36. Sirol M et al. (2004) Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. Circulation 109: 2890-2896
37. Brown DL et al. (1995) Identification of 92-kD gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina. Circulation 91: 2125-2131
38. Cipollone F et al. (2001) Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 104: 921-927
39. Diamant M et al. (2004) Cellular microparticles: new players in the field of vascular disease? Eur J Clin Invest 34: 392-401
40. Jonasson L et al. (1986) Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 6: 131-138
41. Mallat Z et al. (1999) Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 99: 348-353
42. Himber J et al. (2003) Inhibition of tissue factor limits the growth of venous thrombus in the rabbit. J Thromb Haemost 1: 889-895
43. Morawski AM et al. (2004) Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn Reson Med 51: 480-486
44. Flacke S et al. (2001) Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 104: 1280-1285
45. Winter PM et al. (2003) Improved molecular imaging contrast agent for detection of human thrombus. Magn Reson Med 50: 411-416
46. Yu X et al. (2000) High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent. Magn Reson Med 44: 867-872
47. Schmitz SA et al. (2001) USPIO-enhanced direct MR imaging of thrombus: preclinical evaluation in rabbits. Radiology 221: 237-243
48. Johansson LO et al. (2001) A targeted contrast agent for magnetic resonance imaging of thrombus: implications of spatial resolution. J Magn Reson Imaging 13: 615-618
49. Jaffer FA and Weissleder R (2004) Seeing within: molecular imaging of the cardiovascular system. Circ Res 94: 433-445
50. Fayad ZA et al. (2002) Detection of arterial thrombi in vivo by MRI using a fibrin-targeted contrast agent [Abstract II-435]. Circulation 106